Synthesis of an Ammended Analogue of Delavirdine

The efficacy of delavirdine is lower than other FDA approved NNRTIs, therefore, the US department of health and Human Services has recommended its use not as a part of initial therapy but in combination with other drugs. To circumvent this therapeutic difficulty of delavirdine, we amended its structure to develop a novel analogue by replacing its less active indole fragment with a more active anti-HIV prone isatin’s Mannich bases. The molecular assemblage of delavirdine was concurrently also altered by rearranging its vital fragments to allow it to emerge with altogether a different molecular setting.